Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results.
Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are satisfied with the encouraging disease control rate achieved in late stage and heavily pretreated melanoma patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial potential that could be realized through the potential use of LTX-315 in basal cell carcinoma patients. After examining the reassuring data from the Phase II study presented by our partner Verrica Pharmaceuticals during this quarter, we very much look forward to the results of their entire Phase II study, which is expected to be completed during the first half of 2024. Adding to that, we have great expectations for the upcoming study where LTX-315 will be tested in earlier stage melanoma patients in the neoadjuvant NeoLIPA trial at Oslo University Hospital Radiumhospitalet during 2024.”